Invesco
ELVN icon

Invesco’s Enliven Therapeutics ELVN Stock Holding History

Invesco’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.73M Buy
112,972
+51,220
+83% +$2.17M ﹤0.01% 2175
2026
Q1 		$2.42M Buy
61,752
+37,032
+150% +$1.03M ﹤0.01% 2458
2025
Q4 		$381K Buy
24,720
+1,624
+7% +$32.4K ﹤0.01% 3299
2025
Q3 		$473K Buy
23,096
+1,139
+5% +$23K ﹤0.01% 3241
2025
Q2 		$440K Buy
21,957
+913
+4% +$17.3K ﹤0.01% 3211
2025
Q1 		$414K Buy
21,044
+5,972
+40% +$129K ﹤0.01% 3227
2024
Q4 		$339K Buy
15,072
+508
+3% +$13.2K ﹤0.01% 3380
2024
Q3 		$372K Buy
14,564
+264
+2% +$6.11K ﹤0.01% 3345
2024
Q2 		$334K Buy
14,300
+1,811
+15% +$38.1K ﹤0.01% 3453
2024
Q1 		$220K Buy
12,489
+1
+0% +$15 ﹤0.01% 3612
2023
Q4 		$173K Sell
12,488
-6,278
-33% -$76.8K ﹤0.01% 3591
2023
Q3 		$256K Buy
+18,766
New +$316K ﹤0.01% 3511

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Invesco's ELVN Position: Q2 2026 in Review

Invesco increased its Enliven Therapeutics (ELVN) stake by 83% in Q2 2026, buying an estimated $2.17M and bringing the position to 112,972 shares worth $5.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

Invesco first reported a position in ELVN in Q3 2023 and has held it in 12 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Invesco held 112,972 shares of Enliven Therapeutics worth $5.73M as of Q2 2026.
  • Invesco bought 51,220 Enliven Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Enliven Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2175 holding.
  • Invesco first reported a position in Enliven Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.